185 related articles for article (PubMed ID: 20497869)
1. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
5. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration.
To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS
J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reactions to oxaliplatin: experience in a single institute.
Siu SW; Chan RT; Au GK
Ann Oncol; 2006 Feb; 17(2):259-61. PubMed ID: 16282245
[TBL] [Abstract][Full Text] [Related]
7. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
[TBL] [Abstract][Full Text] [Related]
8. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Thomas RR; Quinn MG; Schuler B; Grem JL
Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda A; Goel R; Berdzik J; Leichman CG; Javle M
Oncology (Williston Park); 2004 Nov; 18(13):1671-5; discussion 1676, 1680, 1683-4. PubMed ID: 15648298
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
Park SJ; Lee KY; Park WS; Min SY
Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
[TBL] [Abstract][Full Text] [Related]
15. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
Hewitt MR; Sun W
Clin Colorectal Cancer; 2006 Jul; 6(2):114-7. PubMed ID: 16945166
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions.
Zhang X; Zhao Y; Zheng Y; Dong Y
J Investig Allergol Clin Immunol; 2017; 27(1):65-66. PubMed ID: 28211349
[No Abstract] [Full Text] [Related]
18. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hypersensitivity reactions in patients on H1-receptor antagonists receiving oxaliplatin-based chemotherapy.
Barrett C; Park SJ; Edmondson L; Monga D
J Oncol Pharm Pract; 2022 Apr; 28(3):577-581. PubMed ID: 33789524
[TBL] [Abstract][Full Text] [Related]
20. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
